Evotec SE (EVO) Stock Competitors & Peer Comparison
See (EVO) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| EVO | $2.74 | +1.11% | 973.2M | -3.87 | -$0.71 | N/A |
| TAK | $15.91 | +1.66% | 50.3B | 9.26 | $1.72 | +3.90% |
| HLN | $9.24 | -0.32% | 40.8B | 23.12 | $0.40 | +2.09% |
| TEVA | $33.21 | -1.22% | 38.7B | 11.34 | $2.93 | N/A |
| VTRS | $16.33 | +1.62% | 19B | 6.67 | $2.45 | +2.97% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| RDY | $15.38 | +0.85% | 12.8B | 25.24 | $0.61 | +0.59% |
| ELAN | $24.57 | +0.82% | 12.3B | 25.10 | $0.98 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| LNTH | $109.80 | +0.72% | 7.1B | 18.37 | $5.97 | N/A |
Stock Comparison
EVO vs TAK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TAK has a market cap of 50.3B. Regarding current trading prices, EVO is priced at $2.74, while TAK trades at $15.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TAK's P/E ratio is 9.26. In terms of profitability, EVO's ROE is -0.24%, compared to TAK's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check TAK's competition here
EVO vs HLN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, HLN has a market cap of 40.8B. Regarding current trading prices, EVO is priced at $2.74, while HLN trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas HLN's P/E ratio is 23.12. In terms of profitability, EVO's ROE is -0.24%, compared to HLN's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check HLN's competition here
EVO vs TEVA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TEVA has a market cap of 38.7B. Regarding current trading prices, EVO is priced at $2.74, while TEVA trades at $33.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TEVA's P/E ratio is 11.34. In terms of profitability, EVO's ROE is -0.24%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, EVO is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TEVA's competition here
EVO vs VTRS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, VTRS has a market cap of 19B. Regarding current trading prices, EVO is priced at $2.74, while VTRS trades at $16.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas VTRS's P/E ratio is 6.67. In terms of profitability, EVO's ROE is -0.24%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, EVO is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check VTRS's competition here
EVO vs ITCI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, EVO is priced at $2.74, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ITCI's P/E ratio is -180.64. In terms of profitability, EVO's ROE is -0.24%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, EVO is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ITCI's competition here
EVO vs RDY Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, RDY has a market cap of 12.8B. Regarding current trading prices, EVO is priced at $2.74, while RDY trades at $15.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas RDY's P/E ratio is 25.24. In terms of profitability, EVO's ROE is -0.24%, compared to RDY's ROE of +0.12%. Regarding short-term risk, EVO is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RDY's competition here
EVO vs ELAN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ELAN has a market cap of 12.3B. Regarding current trading prices, EVO is priced at $2.74, while ELAN trades at $24.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ELAN's P/E ratio is 25.10. In terms of profitability, EVO's ROE is -0.24%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, EVO is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ELAN's competition here
EVO vs CTLT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, EVO is priced at $2.74, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CTLT's P/E ratio is -27.84. In terms of profitability, EVO's ROE is -0.24%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, EVO is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check CTLT's competition here
EVO vs LNTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, LNTH has a market cap of 7.1B. Regarding current trading prices, EVO is priced at $2.74, while LNTH trades at $109.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas LNTH's P/E ratio is 18.37. In terms of profitability, EVO's ROE is -0.24%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, EVO is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LNTH's competition here
EVO vs AMRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AMRX has a market cap of 5.5B. Regarding current trading prices, EVO is priced at $2.74, while AMRX trades at $17.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AMRX's P/E ratio is 19.14. In terms of profitability, EVO's ROE is -0.24%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, EVO is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AMRX's competition here
EVO vs INDV Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, INDV has a market cap of 5.2B. Regarding current trading prices, EVO is priced at $2.74, while INDV trades at $41.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas INDV's P/E ratio is 13.89. In terms of profitability, EVO's ROE is -0.24%, compared to INDV's ROE of -1.42%. Regarding short-term risk, EVO is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check INDV's competition here
EVO vs RGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, RGC has a market cap of 3.2B. Regarding current trading prices, EVO is priced at $2.74, while RGC trades at $6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas RGC's P/E ratio is -456.34. In terms of profitability, EVO's ROE is -0.24%, compared to RGC's ROE of -2.32%. Regarding short-term risk, EVO is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RGC's competition here
EVO vs SUPN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SUPN has a market cap of 2.7B. Regarding current trading prices, EVO is priced at $2.74, while SUPN trades at $46.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SUPN's P/E ratio is 13.66. In terms of profitability, EVO's ROE is -0.24%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SUPN's competition here
EVO vs DCPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, EVO is priced at $2.74, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas DCPH's P/E ratio is -11.58. In terms of profitability, EVO's ROE is -0.24%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, EVO is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DCPH's competition here
EVO vs AVDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, EVO is priced at $2.74, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, EVO's ROE is -0.24%, compared to AVDL's ROE of -0.00%. Regarding short-term risk, EVO is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check AVDL's competition here
EVO vs ANIP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ANIP has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.74, while ANIP trades at $84.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ANIP's P/E ratio is 10.28. In terms of profitability, EVO's ROE is -0.24%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, EVO is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ANIP's competition here
EVO vs EMBCV Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, EVO is priced at $2.74, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas EMBCV's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, EVO is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EMBCV's competition here
EVO vs DVAX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.74, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas DVAX's P/E ratio is -41.89. In terms of profitability, EVO's ROE is -0.24%, compared to DVAX's ROE of -0.08%. Regarding short-term risk, EVO is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DVAX's competition here
EVO vs BHC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.74, while BHC trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas BHC's P/E ratio is 1.22. In terms of profitability, EVO's ROE is -0.24%, compared to BHC's ROE of +1.21%. Regarding short-term risk, EVO is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check BHC's competition here
EVO vs HCM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, HCM has a market cap of 1.8B. Regarding current trading prices, EVO is priced at $2.74, while HCM trades at $10.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas HCM's P/E ratio is 3.81. In terms of profitability, EVO's ROE is -0.24%, compared to HCM's ROE of +0.41%. Regarding short-term risk, EVO is less volatile compared to HCM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HCM's competition here
EVO vs TARO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $2.74, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TARO's P/E ratio is 30.05. In terms of profitability, EVO's ROE is -0.24%, compared to TARO's ROE of +0.03%. Regarding short-term risk, EVO is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check TARO's competition here
EVO vs HROW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, HROW has a market cap of 1.6B. Regarding current trading prices, EVO is priced at $2.74, while HROW trades at $42.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas HROW's P/E ratio is 210.35. In terms of profitability, EVO's ROE is -0.24%, compared to HROW's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HROW's competition here
EVO vs PRGO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PRGO has a market cap of 1.4B. Regarding current trading prices, EVO is priced at $2.74, while PRGO trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PRGO's P/E ratio is 3.87. In terms of profitability, EVO's ROE is -0.24%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, EVO is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PRGO's competition here
EVO vs PAHC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, EVO is priced at $2.74, while PAHC trades at $31.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PAHC's P/E ratio is 10.82. In terms of profitability, EVO's ROE is -0.24%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, EVO is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PAHC's competition here
EVO vs ALVO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ALVO has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $2.74, while ALVO trades at $3.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ALVO's P/E ratio is -10.82. In terms of profitability, EVO's ROE is -0.24%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, EVO is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ALVO's competition here
EVO vs COLL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $2.74, while COLL trades at $36.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas COLL's P/E ratio is 4.73. In terms of profitability, EVO's ROE is -0.24%, compared to COLL's ROE of +0.27%. Regarding short-term risk, EVO is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check COLL's competition here
EVO vs ALVOW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ALVOW has a market cap of 1.2B. Regarding current trading prices, EVO is priced at $2.74, while ALVOW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ALVOW's P/E ratio is 24.84. In terms of profitability, EVO's ROE is -0.24%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, EVO is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ALVOW's competition here
EVO vs CRON Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CRON has a market cap of 1B. Regarding current trading prices, EVO is priced at $2.74, while CRON trades at $2.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CRON's P/E ratio is -113.77. In terms of profitability, EVO's ROE is -0.24%, compared to CRON's ROE of -0.00%. Regarding short-term risk, EVO is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CRON's competition here
EVO vs PCRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PCRX has a market cap of 992.8M. Regarding current trading prices, EVO is priced at $2.74, while PCRX trades at $25.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PCRX's P/E ratio is 9.67. In terms of profitability, EVO's ROE is -0.24%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, EVO is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PCRX's competition here
EVO vs ETON Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ETON has a market cap of 977.9M. Regarding current trading prices, EVO is priced at $2.74, while ETON trades at $35.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ETON's P/E ratio is -510.00. In terms of profitability, EVO's ROE is -0.24%, compared to ETON's ROE of -0.06%. Regarding short-term risk, EVO is less volatile compared to ETON. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ETON's competition here
EVO vs AMPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AMPH has a market cap of 960.3M. Regarding current trading prices, EVO is priced at $2.74, while AMPH trades at $21.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AMPH's P/E ratio is 7.43. In terms of profitability, EVO's ROE is -0.24%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, EVO is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AMPH's competition here
EVO vs PETQ Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, EVO is priced at $2.74, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PETQ's P/E ratio is 83.73. In terms of profitability, EVO's ROE is -0.24%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, EVO is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check PETQ's competition here
EVO vs IRWD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, IRWD has a market cap of 679.9M. Regarding current trading prices, EVO is priced at $2.74, while IRWD trades at $4.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas IRWD's P/E ratio is 6.77. In terms of profitability, EVO's ROE is -0.24%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, EVO is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check IRWD's competition here
EVO vs BDSI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, EVO is priced at $2.74, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas BDSI's P/E ratio is 6.82. In terms of profitability, EVO's ROE is -0.24%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, EVO is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check BDSI's competition here
EVO vs TLRY Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TLRY has a market cap of 556.8M. Regarding current trading prices, EVO is priced at $2.74, while TLRY trades at $4.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TLRY's P/E ratio is -7.32. In terms of profitability, EVO's ROE is -0.24%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TLRY's competition here
EVO vs EOLS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, EOLS has a market cap of 469.5M. Regarding current trading prices, EVO is priced at $2.74, while EOLS trades at $7.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas EOLS's P/E ratio is -16.36. In terms of profitability, EVO's ROE is -0.24%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, EVO is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EOLS's competition here
EVO vs AQST Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AQST has a market cap of 436M. Regarding current trading prices, EVO is priced at $2.74, while AQST trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AQST's P/E ratio is -7.20. In terms of profitability, EVO's ROE is -0.24%, compared to AQST's ROE of +1.91%. Regarding short-term risk, EVO is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AQST's competition here
EVO vs KMDA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, KMDA has a market cap of 418.9M. Regarding current trading prices, EVO is priced at $2.74, while KMDA trades at $7.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas KMDA's P/E ratio is 20.74. In terms of profitability, EVO's ROE is -0.24%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, EVO is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check KMDA's competition here
EVO vs CGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CGC has a market cap of 399.3M. Regarding current trading prices, EVO is priced at $2.74, while CGC trades at $0.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CGC's P/E ratio is -2.10. In terms of profitability, EVO's ROE is -0.24%, compared to CGC's ROE of -0.39%. Regarding short-term risk, EVO is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CGC's competition here
EVO vs SNDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SNDL has a market cap of 361.8M. Regarding current trading prices, EVO is priced at $2.74, while SNDL trades at $1.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SNDL's P/E ratio is -46.33. In terms of profitability, EVO's ROE is -0.24%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, EVO is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SNDL's competition here
EVO vs ORGO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ORGO has a market cap of 312.7M. Regarding current trading prices, EVO is priced at $2.74, while ORGO trades at $2.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ORGO's P/E ratio is 81.00. In terms of profitability, EVO's ROE is -0.24%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, EVO is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ORGO's competition here
EVO vs TKNO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TKNO has a market cap of 308.3M. Regarding current trading prices, EVO is priced at $2.74, while TKNO trades at $5.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TKNO's P/E ratio is -17.97. In terms of profitability, EVO's ROE is -0.24%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, EVO is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TKNO's competition here
EVO vs ALIM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, EVO is priced at $2.74, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ALIM's P/E ratio is 5.28. In terms of profitability, EVO's ROE is -0.24%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, EVO is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ALIM's competition here
EVO vs SIGA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SIGA has a market cap of 281.2M. Regarding current trading prices, EVO is priced at $2.74, while SIGA trades at $3.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SIGA's P/E ratio is 14.52. In terms of profitability, EVO's ROE is -0.24%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, EVO is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SIGA's competition here
EVO vs LNDC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, EVO is priced at $2.74, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas LNDC's P/E ratio is -4.04. In terms of profitability, EVO's ROE is -0.24%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, EVO is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LNDC's competition here
EVO vs TYHT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, EVO is priced at $2.74, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TYHT's P/E ratio is -1.61. In terms of profitability, EVO's ROE is -0.24%, compared to TYHT's ROE of -0.65%. Regarding short-term risk, EVO is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TYHT's competition here
EVO vs EMBC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, EMBC has a market cap of 207.1M. Regarding current trading prices, EVO is priced at $2.74, while EMBC trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas EMBC's P/E ratio is 1.34. In terms of profitability, EVO's ROE is -0.24%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, EVO is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check EMBC's competition here
EVO vs LFCR Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, LFCR has a market cap of 193.9M. Regarding current trading prices, EVO is priced at $2.74, while LFCR trades at $5.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas LFCR's P/E ratio is -3.95. In terms of profitability, EVO's ROE is -0.24%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, EVO is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LFCR's competition here
EVO vs DERM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, DERM has a market cap of 182.2M. Regarding current trading prices, EVO is priced at $2.74, while DERM trades at $6.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas DERM's P/E ratio is -17.89. In terms of profitability, EVO's ROE is -0.24%, compared to DERM's ROE of -0.36%. Regarding short-term risk, EVO is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check DERM's competition here
EVO vs REPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, EVO is priced at $2.74, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas REPH's P/E ratio is -8.04. In terms of profitability, EVO's ROE is -0.24%, compared to REPH's ROE of -0.22%. Regarding short-term risk, EVO is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check REPH's competition here
EVO vs ACB Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ACB has a market cap of 175.3M. Regarding current trading prices, EVO is priced at $2.74, while ACB trades at $2.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ACB's P/E ratio is 47.17. In terms of profitability, EVO's ROE is -0.24%, compared to ACB's ROE of -0.14%. Regarding short-term risk, EVO is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ACB's competition here
EVO vs THTX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, EVO is priced at $2.74, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas THTX's P/E ratio is -17.84. In terms of profitability, EVO's ROE is -0.24%, compared to THTX's ROE of +0.17%. Regarding short-term risk, EVO is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check THTX's competition here
EVO vs ASRT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, EVO is priced at $2.74, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ASRT's P/E ratio is -7.10. In terms of profitability, EVO's ROE is -0.24%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, EVO is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ASRT's competition here
EVO vs OGI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, OGI has a market cap of 145M. Regarding current trading prices, EVO is priced at $2.74, while OGI trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas OGI's P/E ratio is -3.96. In terms of profitability, EVO's ROE is -0.24%, compared to OGI's ROE of -0.07%. Regarding short-term risk, EVO is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check OGI's competition here
EVO vs CRDL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CRDL has a market cap of 119.9M. Regarding current trading prices, EVO is priced at $2.74, while CRDL trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CRDL's P/E ratio is -3.70. In terms of profitability, EVO's ROE is -0.24%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, EVO is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CRDL's competition here
EVO vs SCTL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, EVO is priced at $2.74, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SCTL's P/E ratio is -7.86. In terms of profitability, EVO's ROE is -0.24%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, EVO is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check SCTL's competition here
EVO vs PROC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, EVO is priced at $2.74, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PROC's P/E ratio is 1.53. In terms of profitability, EVO's ROE is -0.24%, compared to PROC's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check PROC's competition here
EVO vs CPIX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CPIX has a market cap of 101.1M. Regarding current trading prices, EVO is priced at $2.74, while CPIX trades at $6.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CPIX's P/E ratio is -37.50. In terms of profitability, EVO's ROE is -0.24%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, EVO is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CPIX's competition here
EVO vs OPTN Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, EVO is priced at $2.74, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas OPTN's P/E ratio is -4.42. In terms of profitability, EVO's ROE is -0.24%, compared to OPTN's ROE of +0.45%. Regarding short-term risk, EVO is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check OPTN's competition here
EVO vs ZOM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, EVO is priced at $2.74, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ZOM's P/E ratio is -1.62. In terms of profitability, EVO's ROE is -0.24%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZOM's competition here
EVO vs GRVI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, EVO is priced at $2.74, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas GRVI's P/E ratio is 26.05. In terms of profitability, EVO's ROE is -0.24%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, EVO is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check GRVI's competition here
EVO vs ZYNE Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, EVO is priced at $2.74, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, EVO's ROE is -0.24%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, EVO is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZYNE's competition here
EVO vs SSIC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, EVO is priced at $2.74, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SSIC's P/E ratio is 11.93. In terms of profitability, EVO's ROE is -0.24%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, EVO is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SSIC's competition here
EVO vs BGM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, BGM has a market cap of 64.8M. Regarding current trading prices, EVO is priced at $2.74, while BGM trades at $0.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas BGM's P/E ratio is -1.11. In terms of profitability, EVO's ROE is -0.24%, compared to BGM's ROE of -0.03%. Regarding short-term risk, EVO is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check BGM's competition here
EVO vs VLNS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, EVO is priced at $2.74, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas VLNS's P/E ratio is -1.03. In terms of profitability, EVO's ROE is -0.24%, compared to VLNS's ROE of N/A. Regarding short-term risk, EVO is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check VLNS's competition here
EVO vs INCR Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, INCR has a market cap of 59.4M. Regarding current trading prices, EVO is priced at $2.74, while INCR trades at $1.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas INCR's P/E ratio is -5.84. In terms of profitability, EVO's ROE is -0.24%, compared to INCR's ROE of -0.09%. Regarding short-term risk, EVO is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check INCR's competition here
EVO vs DRRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, EVO is priced at $2.74, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas DRRX's P/E ratio is -4.44. In terms of profitability, EVO's ROE is -0.24%, compared to DRRX's ROE of +0.13%. Regarding short-term risk, EVO is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check DRRX's competition here
EVO vs JUPW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, EVO is priced at $2.74, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas JUPW's P/E ratio is -2.41. In terms of profitability, EVO's ROE is -0.24%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, EVO is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check JUPW's competition here
EVO vs IXHL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, IXHL has a market cap of 40.9M. Regarding current trading prices, EVO is priced at $2.74, while IXHL trades at $3.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas IXHL's P/E ratio is -4.99. In terms of profitability, EVO's ROE is -0.24%, compared to IXHL's ROE of -1.23%. Regarding short-term risk, EVO is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check IXHL's competition here
EVO vs QLI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, EVO is priced at $2.74, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas QLI's P/E ratio is -4.92. In terms of profitability, EVO's ROE is -0.24%, compared to QLI's ROE of -0.16%. Regarding short-term risk, EVO is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check QLI's competition here
EVO vs ZYBT Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ZYBT has a market cap of 33M. Regarding current trading prices, EVO is priced at $2.74, while ZYBT trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ZYBT's P/E ratio is -3.17. In terms of profitability, EVO's ROE is -0.24%, compared to ZYBT's ROE of -0.26%. Regarding short-term risk, EVO is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ZYBT's competition here
EVO vs HEXO Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, EVO is priced at $2.74, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas HEXO's P/E ratio is -0.26. In terms of profitability, EVO's ROE is -0.24%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, EVO is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check HEXO's competition here
EVO vs RMTI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, RMTI has a market cap of 25.7M. Regarding current trading prices, EVO is priced at $2.74, while RMTI trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas RMTI's P/E ratio is -4.34. In terms of profitability, EVO's ROE is -0.24%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, EVO is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RMTI's competition here
EVO vs TXMD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TXMD has a market cap of 24.4M. Regarding current trading prices, EVO is priced at $2.74, while TXMD trades at $2.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TXMD's P/E ratio is 107.49. In terms of profitability, EVO's ROE is -0.24%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, EVO is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TXMD's competition here
EVO vs CYTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, EVO is priced at $2.74, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CYTH's P/E ratio is -0.80. In terms of profitability, EVO's ROE is -0.24%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, EVO is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check CYTH's competition here
EVO vs TLPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, TLPH has a market cap of 21.1M. Regarding current trading prices, EVO is priced at $2.74, while TLPH trades at $1.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas TLPH's P/E ratio is -3.32. In terms of profitability, EVO's ROE is -0.24%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check TLPH's competition here
EVO vs EVOK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, EVO is priced at $2.74, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas EVOK's P/E ratio is -7.97. In terms of profitability, EVO's ROE is -0.24%, compared to EVOK's ROE of -1.01%. Regarding short-term risk, EVO is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check EVOK's competition here
EVO vs AYTU Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AYTU has a market cap of 17.6M. Regarding current trading prices, EVO is priced at $2.74, while AYTU trades at $2.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AYTU's P/E ratio is -1.13. In terms of profitability, EVO's ROE is -0.24%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, EVO is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AYTU's competition here
EVO vs QNTM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, QNTM has a market cap of 16.7M. Regarding current trading prices, EVO is priced at $2.74, while QNTM trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas QNTM's P/E ratio is -0.45. In terms of profitability, EVO's ROE is -0.24%, compared to QNTM's ROE of -6.22%. Regarding short-term risk, EVO is less volatile compared to QNTM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check QNTM's competition here
EVO vs ACRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, EVO is priced at $2.74, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ACRX's P/E ratio is -0.31. In terms of profitability, EVO's ROE is -0.24%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, EVO is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ACRX's competition here
EVO vs OPTH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, OPTH has a market cap of 13.5M. Regarding current trading prices, EVO is priced at $2.74, while OPTH trades at $4.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas OPTH's P/E ratio is -15.37. In terms of profitability, EVO's ROE is -0.24%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, EVO is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check OPTH's competition here
EVO vs COSM Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, COSM has a market cap of 10.7M. Regarding current trading prices, EVO is priced at $2.74, while COSM trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas COSM's P/E ratio is -0.28. In terms of profitability, EVO's ROE is -0.24%, compared to COSM's ROE of -0.96%. Regarding short-term risk, EVO is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check COSM's competition here
EVO vs AGRX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, EVO is priced at $2.74, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas AGRX's P/E ratio is -0.89. In terms of profitability, EVO's ROE is -0.24%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, EVO is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check AGRX's competition here
EVO vs BFRIW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, BFRIW has a market cap of 9M. Regarding current trading prices, EVO is priced at $2.74, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.24%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, EVO is more volatile compared to BFRIW. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check BFRIW's competition here
EVO vs NLTX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, EVO is priced at $2.74, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas NLTX's P/E ratio is -0.28. In terms of profitability, EVO's ROE is -0.24%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, EVO is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check NLTX's competition here
EVO vs LCI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, EVO is priced at $2.74, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas LCI's P/E ratio is -0.04. In terms of profitability, EVO's ROE is -0.24%, compared to LCI's ROE of +1.66%. Regarding short-term risk, EVO is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check LCI's competition here
EVO vs YCBD Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, YCBD has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $2.74, while YCBD trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas YCBD's P/E ratio is -1.71. In terms of profitability, EVO's ROE is -0.24%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, EVO is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check YCBD's competition here
EVO vs ADMP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, EVO is priced at $2.74, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ADMP's P/E ratio is -0.08. In terms of profitability, EVO's ROE is -0.24%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, EVO is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check ADMP's competition here
EVO vs GELS Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, GELS has a market cap of 6M. Regarding current trading prices, EVO is priced at $2.74, while GELS trades at $0.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas GELS's P/E ratio is -1.30. In terms of profitability, EVO's ROE is -0.24%, compared to GELS's ROE of -0.43%. Regarding short-term risk, EVO is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check GELS's competition here
EVO vs MNK Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, EVO is priced at $2.74, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas MNK's P/E ratio is -0.44. In terms of profitability, EVO's ROE is -0.24%, compared to MNK's ROE of -0.26%. Regarding short-term risk, EVO is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check MNK's competition here
EVO vs FLGC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, EVO is priced at $2.74, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas FLGC's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.24%, compared to FLGC's ROE of -2.70%. Regarding short-term risk, EVO is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check FLGC's competition here
EVO vs RDHL Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, RDHL has a market cap of 2.8M. Regarding current trading prices, EVO is priced at $2.74, while RDHL trades at $0.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas RDHL's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to RDHL's ROE of +2.91%. Regarding short-term risk, EVO is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check RDHL's competition here
EVO vs PLXP Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, EVO is priced at $2.74, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PLXP's P/E ratio is -0.22. In terms of profitability, EVO's ROE is -0.24%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, EVO is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check PLXP's competition here
EVO vs SHPH Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SHPH has a market cap of 2.4M. Regarding current trading prices, EVO is priced at $2.74, while SHPH trades at $4.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SHPH's P/E ratio is -0.19. In terms of profitability, EVO's ROE is -0.24%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, EVO is less volatile compared to SHPH. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SHPH's competition here
EVO vs ATNX Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, EVO is priced at $2.74, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas ATNX's P/E ratio is -0.02. In terms of profitability, EVO's ROE is -0.24%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, EVO is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check ATNX's competition here
EVO vs CPHI Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, CPHI has a market cap of 2M. Regarding current trading prices, EVO is priced at $2.74, while CPHI trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas CPHI's P/E ratio is -0.80. In terms of profitability, EVO's ROE is -0.24%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, EVO is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check CPHI's competition here
EVO vs PROCW Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, EVO is priced at $2.74, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas PROCW's P/E ratio is N/A. In terms of profitability, EVO's ROE is -0.24%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, EVO is more volatile compared to PROCW. This indicates potentially higher risk in terms of short-term price fluctuations for EVO.Check PROCW's competition here
EVO vs SNOA Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SNOA has a market cap of 1.9M. Regarding current trading prices, EVO is priced at $2.74, while SNOA trades at $1.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SNOA's P/E ratio is -1.19. In terms of profitability, EVO's ROE is -0.24%, compared to SNOA's ROE of -0.88%. Regarding short-term risk, EVO is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SNOA's competition here
EVO vs SXTC Comparison June 2026
EVO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, EVO stands at 973.2M. In comparison, SXTC has a market cap of 1.9M. Regarding current trading prices, EVO is priced at $2.74, while SXTC trades at $2.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
EVO currently has a P/E ratio of -3.87, whereas SXTC's P/E ratio is 1.09. In terms of profitability, EVO's ROE is -0.24%, compared to SXTC's ROE of -0.15%. Regarding short-term risk, EVO is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for EVO.Check SXTC's competition here